Review
Oncology
Serena Ceddia, Giovanni Codacci-Pisanelli
Summary: Brain metastases are common in patients with ALK-translocated non-small cell lung cancer and are typically treated with radiotherapy. However, this can lead to severe late toxic side effects, prompting the use of ALK inhibitors such as crizotinib, alectinib, and brigatinib which have shown excellent activity against brain metastases. Starting treatment with specific inhibitors in asymptomatic patients and using radiotherapy when needed provides the best quality of life for patients.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Immunology
Na Li, Jiahong Wang, Xianquan Zhan
Summary: This study identified two reliable immune-related gene signature models that were significantly associated with prognosis and tumor microenvironment cell infiltration in LUAD and LUSC, respectively. Evaluation of these models could help predict response to immunotherapy and guide immunotherapy strategies.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Surgery
Piaopiao Li, Xuemei Kuang, Tingting Zhang, Lei Ma
Summary: Using a network approach, this study found that lung squamous carcinoma (LUSC) and lung adenocarcinoma (LUAD) share similar gene expression patterns and regulatory patterns, and have 46 highly connected hub genes in common. COL5A2 may be a risk factor for poor prognosis in LUSC and LUAD patients.
FRONTIERS IN SURGERY
(2022)
Article
Oncology
Dahua Liu, Min An, Guimin Wen, Yanan Xing, Pu Xia
Summary: With the high incidence and mortality rate of lung cancer, it is of great importance to analyze the molecular mechanism and identify early diagnosis markers. SLC3A2 protein, which is highly expressed in lung cancer, plays a crucial role in tumorigenesis and development, and has the potential to become a new target for tumor treatment. The levels of SLC3A2 in serum and tissue can serve as prognostic markers for lung cancer and provide valuable insights for diagnosis, treatment, and prognosis.
Article
Pharmacology & Pharmacy
Haoyue Hu, Songtao Tan, Meng Xie, Peng Guo, Qiang Yu, Juan Xiao, Kangrui Zhao, Qiong Liao, Yi Wang
Summary: In non-small cell lung cancer, concurrent genetic alterations of epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are rare, but their clinical and pathological characteristics are not well-defined, and the optimal treatment approach remains controversial. This report presents a case of stage IV lung adenocarcinoma with both EGFR and ALK mutations, along with high PD-L1 expression. The patient initially received treatment with EGFR tyrosine kinase inhibitors (TKIs), but the disease progressed, and regression was achieved following a switch to ALK-TKI therapy and local radiotherapy. Our report also provides a comprehensive summary of the clinical and pathological features, as well as treatment strategies, for NSCLC patients with concurrent EGFR mutation and ALK rearrangement.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Qiyi Meng, Yujie Dong, Hong Tao, Liang Shi, Li Tong, Junfang Tang, Shucai Zhang, Zhe Liu
Summary: ALK rearrangement in squamous cell carcinoma of the lung is rare, with patients typically lacking sufficient clinical data. This study identified eight cases of SCC with ALK rearrangement, with two patients receiving crizotinib as second-line therapy, one showing stable disease for six months and the other showing disease progression with a shorter progression-free survival. Overall, ALK-inhibitor therapy benefited ALK-rearranged SCC patients, particularly non-smokers identified through IHC+/FISH+.
Review
Biochemistry & Molecular Biology
Aaron C. Tan, Nick Pavlakis
Summary: The management of advanced lung cancer has been transformed by the identification of targetable oncogenic driver alterations, including ALK gene rearrangements. ALK tyrosine kinase inhibitors have become the first-line treatment options for advanced ALK rearranged NSCLC. However, drug resistance remains a challenge, and the role of anti-angiogenic therapy in ALK rearranged NSCLC needs further exploration.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Marianne Oulhen, Patrycja Pawlikowska, Tala Tayoun, Marianna Garonzi, Genny Buson, Claudio Forcato, Nicolo Manaresi, Agathe Aberlenc, Laura Mezquita, Yann Lecluse, Pernelle Lavaud, Charles Naltet, David Planchard, Benjamin Besse, Francoise Farace
Summary: Gatekeeper mutations are only identified in 50% of cases at resistance to ALK-TKIs. Circulating tumor cells (CTCs) are useful tools in identifying additional resistance mechanisms and can be sequenced at the single-cell level. Comprehensive analysis of CTCs reveals wide copy number alteration (CNA) heterogeneity and high chromosomal instability (CIN) at resistance to ALK-TKIs, providing valuable insights for precision medicine and overcoming resistance to ALK-targeted therapies.
NPJ PRECISION ONCOLOGY
(2021)
Article
Oncology
Ines Mota, Enrico Patrucco, Cristina Mastini, Navin R. Mahadevan, Tran C. Thai, Elisa Bergaggio, Taek-Chin Cheong, Giulia Leonardi, Elif Karaca-Atabay, Marco Campisi, Teresa Poggio, Matteo Menotti, Chiara Ambrogio, Dario L. Longo, Susan Klaeger, Hasmik Keshishian, Zsofia M. Sztupinszki, Zoltan Szallasi, Derin B. Keskin, Jonathan S. Duke-Cohan, Bruce Reinhold, Steven A. Carr, Catherine J. Wu, Kelly D. Moynihan, Darrell J. Irvine, David A. Barbie, Ellis L. Reinherz, Claudia Voena, Mark M. Awad, Rafael B. Blasco, Roberto Chiarle
Summary: Mota et al. demonstrate that immunogenic ALK peptides can enhance the response to immune checkpoint blockade in ALK-rearranged NSCLC mouse models. They also identify immunogenic human ALK peptides for future translational research.
Article
Oncology
Jin-Dong Li, Cheng-Yan Jin, Yan Zhang, Hang Guo, Guang-Lei Zhang, Chun-Guang Wang
Summary: This case report describes a patient with lung cancer who experienced histopathological transformation from squamous-cell carcinoma to large cell neuroendocrine carcinoma with a small fraction of small cell carcinoma.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Oncology
Kamya Sankar, Sunitha Nagrath, Nithya Ramnath
Summary: Non-small cell lung cancer is commonly associated with ALK rearrangements, with approximately 5-6% of cases affected. Although ALK-rearranged tumors respond well to targeted therapies, they are often resistant to immunotherapies. This article explores the mechanisms behind this immune evasion and discusses the potential of novel immunotherapeutic approaches for ALK-rearranged non-small cell lung cancer.
Review
Health Care Sciences & Services
Nina Pujol, Simon Heeke, Christophe Bontoux, Jacques Boutros, Marius Ilie, Veronique Hofman, Charles-Hugo Marquette, Paul Hofman, Jonathan Benzaquen
Summary: Molecular diagnosis of lung cancer is a constantly evolving field that requires repeated testing to establish accurate molecular diagnosis and track disease evolution. The emergence of next-generation sequencing (NGS) has greatly facilitated molecular profiling in lung cancer.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Spectroscopy
Yafeng Qi, Lin Yang, Bangxu Liu, Li Liu, Yuhong Liu, Qingfeng Zheng, Dameng Liu, Jianbin Luo
Summary: In this study, Raman spectroscopy and deep learning were utilized for accurate and stain-free intraoperative diagnosis. By treating Raman spectral signals as sequences and converting them into two-dimensional Raman spectrograms using short-time Fourier transform as input, high performance deep learning models were achieved, surpassing traditional methods in accuracy and sensitivity.
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
(2022)
Review
Oncology
Yu Lei, Yan Lei, Xiang Shi, Jingjing Wang
Summary: Non-small cell lung cancer (NSCLC) is a malignant tumor with a high morbidity and mortality rate, and the EML4-ALK fusion gene is one of the most important pathogenic driver genes of NSCLC. With the development of molecular targeted research, the introduction of four generations of targeted drugs for EML4-ALK has significantly benefited patients.
Article
Oncology
Zizong Wang, Yushuai Han, Houquan Tao, Mengxiang Xu, Zhengchuang Liu, Jianhua Zhu, Wei Li, Jie Ma, Zhifang Liu, Weiran Wang, Tonghui Ma
Summary: ALK rearrangement, also known as the 'diamond mutation' in non-small cell lung cancer (NSCLC), plays a crucial role in determining the suitable candidates for ALK inhibitors. In this study, DNA-based next-generation sequencing (NGS) was used to identify ALK rearrangement-positive NSCLC cases and analyze their genomic breakpoints. The findings highlight the necessity of using RNA-based assays to confirm functional RNA fusions in cases with uncommon or frameshift rearrangements.
MOLECULAR ONCOLOGY
(2023)
Article
Oncology
Page Widick, Ritu R. Gill, Charlene Mantia, Daniel B. Costa, Deepa Rangachari
CLINICAL LUNG CANCER
(2020)
Article
Gastroenterology & Hepatology
Li Chen, Moli Huang, Jasmine Plummer, Jian Pan, Yan Yi Jiang, Qian Yang, Tiago Chedraoui Silva, Nicole Gull, Stephanie Chen, Ling Wen Ding, Omer An, Henry Yang, Yulan Cheng, Jonathan W. Said, Ngan Doan, Winand N. M. Dinjens, Kevin M. Waters, Richard Tuli, Simon A. Gayther, Samuel J. Klempner, Benjamin P. Berman, Stephen J. Meltzer, De-Chen Lin, H. Phillip Koeffler
Review
Oncology
Samuel J. Klempner, David Fabrizio, Shalmali Bane, Marcia Reinhart, Tim Peoples, Siraj M. Ali, Ethan S. Sokol, Garrett Frampton, Alexa B. Schrock, Rachel Anhorn, Prasanth Reddy
Article
Oncology
Ana Pertejo-Fernandez, Biagio Ricciuti, Sarah P. Hammond, Francisco M. Marty, Gonzalo Recondo, Deepa Rangachari, Daniel B. Costa, Mark M. Awad
Editorial Material
Oncology
Samuel J. Klempner, Aaron N. Hata
Article
Oncology
Christie Y. Jeon, Yu-Chen Lin, Samuel J. Klempner, Bechien U. Wu, Sungjin Kim, Kevin M. Waters, Robert W. Haile
CANCER PREVENTION RESEARCH
(2020)
Editorial Material
Oncology
Samuel J. Klempner, Vivek Upadhyay, Joseph Chao
CLINICAL CANCER RESEARCH
(2020)
Article
Oncology
Arturo Loaiza-Bonilla, Al B. Benson, Axel Grothey, Misagh Karimi, Samuel J. Klempner, Daniel Lin, Reshma Mahtani, Heloisa P. Soares
Summary: Genomic testing is becoming crucial in cancer diagnosis and treatment decision-making, especially in gastrointestinal cancers like colorectal cancer. Advancements in technology allow for noninvasive screening for CRC through blood or stool tests, while also providing prognostic information and guiding therapy selection.
Article
Oncology
Minsuk Kwon, Minae An, Samuel J. Klempner, Hyuk Lee, Kyoung-Mee Kim, Jason K. Sa, Hee Jin Cho, Jung Yong Hong, Taehyang Lee, Yang Won Min, Tae Jun Kim, Byung-Hoon Min, Woong-Yang Park, Won Ki Kang, Kyu-Tae Kim, Seung Tae Kim, Jeeyun Lee
Summary: The study shows that patients with microsatellite instability and elevated mutational burden in gastric cancer are associated with clinical response to anti-PD-1 antibodies. By combining whole-exome sequencing with single-cell RNA sequencing, dynamic tumor evolution with collapse of mutational architecture in responders is identified. Diversity in T-cell receptor repertoire is linked to better response to pembrolizumab.
Article
Oncology
David A. Drew, Samuel J. Klempner, Andrew T. Chan
Summary: Early detection and interception of gastric cancer globally is limited, especially for individuals without established hereditary risk factors. Establishing biomarkers using multiple-omic approaches may be crucial for identifying individuals at risk and for more intensive evaluation. Multifactorial risk assessment is needed for precision prevention and early detection of gastric cancer.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2021)
Article
Oncology
Jennifer Y. Wo, Jeffrey W. Clark, Christine E. Eyler, Mari Mino-Kenudson, Samuel J. Klempner, Jill N. Allen, Florence K. Keane, Aparna R. Parikh, Eric Roeland, Lorraine C. Drapek, David P. Ryan, Ryan B. Corcoran, Emily Van Seventer, Isobel J. Fetter, Heather A. Shahzade, Melin J. Khandekar, Michael Lanuti, Christopher R. Morse, Rebecca S. Heist, Christine A. Ulysse, Benjamin Christopher, Christian Baglini, Beow Y. Yeap, John T. Mullen, Theodore S. Hong
Summary: The study demonstrated the feasibility of neoadjuvant FOLFIRINOX followed by chemoradiation for locally advanced gastric or gastroesophageal cancer, with a high rate of pathologic complete response. ctDNA shows promise as a predictor for postoperative recurrence.
CLINICAL CANCER RESEARCH
(2021)
Review
Oncology
Jasmine Huynh, Kanishka Patel, Jun Gong, May Cho, Midhun Malla, Aparna Parikh, Samuel Klempner
Summary: Immunotherapy in the treatment of gastroesophageal cancer is evolving and showing promising results, especially with adjuvant immunotherapy and combination therapies. However, challenges remain in treating PD-L1 negative subgroups, indicating the need for further research in biologic understanding and effective therapies. Combination angiogenesis inhibitors and immunotherapy show potential, but more studies are required to optimize treatment strategies.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2021)
Article
Oncology
Samuel J. Klempner, Johanna C. Bendell, Victoria Meucci Villaflor, Laura LaNiel Tenner, Stacey M. Stein, James B. Rottman, Girish S. Naik, Cynthia A. Sirard, Michael H. Kagey, Marya F. Chaney, John H. Strickler
Summary: The study evaluated the safety and efficacy of combination therapy with DKN-01 and pembrolizumab in patients with advanced esophago-gastric cancer, finding better therapeutic outcomes in patients with high DKK1 expression, independent of PD-L1 expression.
MOLECULAR CANCER THERAPEUTICS
(2021)
Article
Oncology
Adi Diab, Omid Hamid, John A. Thompson, Willeke Ros, Ferry A. L. M. Eskens, Toshihiko Doi, Siwen Hu-Lieskovan, Samuel J. Klempner, Bishu Ganguly, Catherine Fleener, Xiao Wang, Tenshang Joh, Ken Liao, Shahram Salek-Ardakani, Carrie Turich Taylor, Jeffrey Chou, Anthony B. El-Khoueiry
Summary: This study investigates the potential of Ivuxolimab in the treatment of cancer. The results demonstrate that Ivuxolimab is well tolerated and safe, and shows anti-tumor activity. Additionally, this study also finds that Ivuxolimab can activate the immune system, enhancing T-cell activation and proliferation, and has a certain control effect on tumors.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Andrew Hendifar, Edik M. Blais, Brian Wolpin, Vivek Subbiah, Eric Collisson, Isha Singh, Timothy Cannon, Kenna Shaw, Emanuel F. Petricoin, Samuel Klempner, Emily Lyons, Andrea Wang-Gillam, Michael J. Pishvaian, Eileen M. O'Reilly
Summary: In pancreatic cancer patients with RAF family alterations, different mutational subgroups were identified and their clinical characteristics were determined, which may contribute to the development of future treatment strategies.
JCO PRECISION ONCOLOGY
(2021)
